Nasdaq
$3.17▼ 0.47%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $208.8MShares out 65.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 10.13Pre-market26.10.13 21:01ARSOther#●●●#●●●
GALECTIN THERAPEUTICS INC
Galectin Therapeutics Inc has filed its Annual Report to Security Holders (ARS) for the fiscal year ended December 31, 2025. This report provides a comprehensive overview of the company's financial condition and business operations.…more
$3.17-0.47%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13Pre-market26.10.13 21:00DEFA14AOther
GALECTIN THERAPEUTICS INC
Galectin Therapeutics has filed additional proxy solicitation materials for its shareholder meeting. This filing is part of the company's procedural requirements as a registrant to facilitate the processing of agenda items for the upcoming shareholder meeting.…more
$3.17-0.47%vs prev closeView filingShare - 10.13Pre-market26.10.13 21:00DEF 14AOther
GALECTIN THERAPEUTICS INC
Galectin Therapeutics will hold its 2026 annual meeting of stockholders on December 3, 2026, with key proposals including an amendment to increase authorized common stock from 150 million to 250 million shares and the reservation of an additional 3 million shares for its equity incentive plan. Stockholders of record as of October 6, 2026, are eligible to vote on these matters, as well as the election of directors and the ratification of the independent auditor.…more
$3.17-0.47%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.6Pre-market26.10.06 21:00#●●●#●●●
Galectin Therapeutics to Present Clinical Data at AASLD and Submits Phase 3 Protocol…more
Galectin Therapeutics will present clinical data on belapectin for MASH cirrhosis at the AASLD meeting and has submitted its Phase 3 trial protocol to the FDA. While these represent progress in drug development, the company remains in the pre-approval stage, making future clinical results and regulatory decisions critical.…more
$3.17-0.47%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.10Pre-market26.09.10 21:00
●●●●●●●● ●●●●● ●●●●●●
Galectin Therapeutics announced that its management will present and hold one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference. This is a standard investor relations event and does not provide immediate material impact on the stock.…more
$3.17-0.47%vs prev close - 8.14Pre-market26.08.14 21:00
●●●●●●●● ●●●●● ●●●●●●
Galectin Therapeutics has reached an agreement with the FDA on the Phase 3 trial design for its MASH drug, belapectin, with a protocol submission expected in the third quarter. Additionally, the company significantly strengthened its balance sheet by converting approximately $105.8 million in debt into common stock.…more
$3.17-0.47%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report